Clinuvel sends regular email updates on its progress, as well as published announcements and analyst reports. You can subscribe to this database below.
Subscribing to Clinuvel's email updates service indicates your acceptance of our Privacy Policy.
Tagged under
Share Price
Buy : 1.65
Sell : 1.7
First : 0
Last : 0
High : 0
Low : 0
ASX: CUV 20 mins delay.
Volume : Trades:
Last Traded : 17-May-2012 15:20:43
Investors' Blog Posts
Earlier today we announced that two health insurers in Switzerland had agreed to reimburse SCENESSE® (afamelanotide) for the rare disease...
Read More
Those who have taken an interest in Clinuvel will have learned with joy that, on Monday February 6th, the company announced its first...
Read More
Earlier this week we unveiled a major update to our online presence with the release of our new-look website and the launch of Mothers...
Read MoreInvestor Spotlight
Contents: INTRODUCTION ERYTHROPOIETIC PROTOPORPHYRIA (EPP) NONSEGMENTAL VITILIGO (NSV) CLINUVEL BUSINESS MODEL CORPORATE MILESTONES CHAIR's LETTER MANAGING DIRECTOR’S REPORT FINANCIALS ADDITIONAL INFORMATION REQUIRED BY THE ASX MARKET PERFORMANCE GLOSSARY ... Read more |
Related Webcasts
Vitiligo is a skin disorder which causes the loss of pigment - melanin - in the skin. Though it affects around 45 million people worldwide,... Watch now |
On 31 January 2012 Swiss TV channel Telezueri aired a report on erythropoietic protoporphyria (EPP), a rare genetic disorder which causes ab... Watch now |
Following Clinuvel's landmark filing of a marketing authorisation application for the drug SCENESSE® (afamelanotide) with the European Medic... Watch now |
